Michael’s Cause contributes 100% of proceeds for programs, grants, and projects that support its mission to provide and appropriate funds that benefit the community for which it serves. Funds are not to be used for institutional, administrative, overhead, or indirect costs, only direct patient care or research.
3/29/2021 $20,000Ryan Schultz - Ramps for house
12/28/2020$100,000.00Charley's Fund - The Duchenne Program at UMass Medical School. Duchenne Clinic Funding
12/28/2020$10,000.00Jett Foundation - Funding for Accessible Van for the Keegan Moore - 12 years old Kyle, TX
11/8/2020$11,333.00Walking Strong - Accessible Van for Rickey Wheeler
9/4/2020$10,000.00MGH Institute of Health Professions - Elise Townsend, PhD, DPT, PCS. DMD Motor Outcomes Trajectories Project
8/22/2020$10,500.00Gibraltor Home Improvement - Accessible Ramp for Omari Stennett
5/21/2020$5,500.00Linda Medina - Funeral Expense for Son Jesus Garcia Medina
4/20/2020$20,000.00Team Joseph Corona Virus Relief Fund Marissa Penrod
3/3/2020 $15,484.00Matthew DeRicci Abby Lifts Hoyer Lift
1/26/2020$66,667.00University of Missouri Gene Therapy Dr. Dongsen Duan Study of pathway for Gene Therapy
05/22/2019$147,333Of Mice and Measures, Casimir Video Scales, Electrical Imendance Myography. In Collaboration with Charley's Find, Pietro's Fight and Ryan's Quest.
07/17/2019$50,000Funding towards an accessible van for Brandon Petronzi
05/15/2018$25,000Oteoprotegerin (OPG) - Dr. Jerome Frenette University of Laval. OPG Bone Protector Rescues Fast Twitch Muscles.
05/15/2018$15,000Quercetin - Dr. Josh Selsby University of Iowa: Effects of a Quercetin Cocktail.
12/27/2017$30,000DMD Therapeutics. Dr. Ron Berenson/Dr. Carlo Rago - OPG Eficacy Study
10/21/2017$35,000Team Joseph - Dr. John Lynn Jeffries. Phrixus Pharmaceuticals. Carmaseal
09/27/2017$10,350DMD Therapeutics. Dr. Ron Berenson/Dr. Carlo Rago - OPG Eficacy Study
09/20/2017$24,840University of Missouri OPG - Dr. Dongsheg Duau. OPG Confirmation Study - funding to Ryans Quest who paid Univ of Missouri
04/07/2017$50,000Montelukast University of Missouri - Montelukast. Dr.Donsheng Duan / Dr. Bob McDonald.
04/07/2017$37,500Kennedy Krieger Institute Myoblast Therapy - Myoblasts derived from IPSC's. Dr. Kathryn Wagner
01/15/2017$25,000DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.
08/08/2016$15,000Phrixus Pharmaceuticals - Carmeseal - Clinical Trial - for treatment of heart failure and respiratory dysfunction in DMD
08/04/2016$100,000DMD Therapeutics - Relaxin - Dr. Ronald Berenson. Anti-Fibrotic agent to help with fibrosis in treating Duchenne Muscular Dystrophy
04/15/2016$15,000Project Goldilocks: Jackson Laboratories - Better Mouse Model for Duchenne testing.
03/20/2016$70,000DDID 100108 Oteoprotegerin (OPG): Dr. Jerome Frenette - OPG Bone Protector rescues fast twitch muscles
12/14/2015$40,000DDID # 100084 - Seratonin Modulators in Zebra Fish - Dr Louis Kunkel (Boston Childrens) - Effects of Seratonin Modulators in Zebra Fish and Mice
10/01/2015 $10,000Grant/Donation - Hugo W. Moser - Hugo H Moser Research Laboratory - Fund Dr Wagner Laboratory for research.
07/28/2015$5,000Treat NMD / Tact Review: Funding for Tact Review - Fund research for review committee on DMD research treatments
06/27/2015$10,000DDID # 100094 Plasma Micro RNA Profiling: Dr Julie Saba (Children's Hospital and Research Center at Oakland - S1P Lyaselnibitor Pilot in MDX Mice
05/12/2015$70,000DDID 10096 Reveragen VBP15. This research project will be an alternative to commonly used glucocorticoids with less side effects.
03/08/2015$50,000DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.
03/08/2015$25,000DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.
11/6/2014$70,000Phase I/IIa Follistatin Gene Therapy Trial. Dr. Jerry Mendell, Director Center for Gene Therapy at Nationwide Children's Hospital, Columbus Ohio. Gene therapy is revolutionary science in our continued fight for better treatments and a future cure for Duchenne.
10/9/2014$20,000Natural hormone study that has effects on muscle that may benefit patients with DMD. In animal studies it has been demonstrated to regenerate damaged skeletal muscle.
08/07/2014$25,000DDID #100087 - Suppressing the level of inflammation in the muscle - Keith Foster, University of Reading, UK
07/15/2014$30,000Halo Therapeutics: HT100 Phase 1/2, Anti Fibriotic agent for the treatment of Duchenne Muscular Dystrophy.
01/04/2014$7,500Natural hormone which has the ability to regenerate muscle, reduce scarring, and improve cardiac function
12/19/2013$20,000DDID #100077 Multicenter randomized double-blind dose titration phase II study in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen and Isosorbide Dinitrate. Conducted by Emillio Clementi, MD Phd, professor of pharmacology, Department of Biomedical and Clinical Sciences, University of Milano-E.Medea Scientific Institute.
12/17/2013$5,000Assist in payment to O’Neill and Associates for their lobbying efforts to help further research in DMD.
11/08/2013$15,000DDID #100071 Quercetin - Determining the mechanisms whereby a Quercetin enriched diet interrupts disease process in DMD.
06/28/2013$70,000Halo Therapeutics: HT100 Phase 1/2, Anti Fibriotic agent for the treatment of Duchenne Muscular Dystrophy.
03/26/2013$15,000Hugo W. Moser Research Institute at Kennedy Kreiger for Duchenne Muscular Dystrophy Research
01/27/2013$5,000Superior Mouse Model for DMD drug development.
01/04/2013$10,000Measurement of in vivo respiratory and cardiac function during dietary enrichment in animal models of DMD.
01/04/2013$5,000Development of Dystrophin Independent Therapy for DMD.
06/22/2012$10,000Muscle regeneration available research available with compounds delivered as nutraceutical. Using an unbiased screen a genetic pathway was identified and associated compounds that regenerate muscle in Duchenne Muscular Dystrophy mouse and fly models. Funding will assist in furthering research in this area.
5/22/2012$30,000Preparation of the Anti-Fibrotic Halofuginone for use in a multi-center Phase II clinical trial. Halofuginone is an anti-fibrotic and muscle regeneration promoter. To date 1.1 million dollars has been funded to help this project get to phase II clinical trial.
04/06/2012$5,500.00The effects of Poloxamer-188 (Carmeseal) on cardiac and skeletal muscle function in MDX mice. Cardiac Function plays an important role in those affected by DMD. Funding will help further research with this drug to see hopeful benefit.
04/06/2012$1,000Duchenne Dashboard Phases V and VI. The Duchenne Dashboard allows foundations to co-identify co-understand and co-fund projects in order to conquer Duchenne Muscular Dystrophy. Funding in this area is necessary to maintain upgrades to the Dashboard.